- Home
- ZVRA vs PRTA Comparison
ZVRA vs PRTA Comparison
Compare ZVRA & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ZVRA | PRTA |
|---|---|---|
| Founded | 2006 | 2012 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 499.9M | 595.9M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | ZVRA | PRTA |
|---|---|---|
| Price | $8.16 | $9.98 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $21.71 | $18.86 |
| AVG Volume (30 Days) | ★ 1.2M | 600.6K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.54 | N/A |
| Revenue | ★ $84,388,000.00 | $11,786,000.00 |
| Revenue This Year | $333.25 | N/A |
| Revenue Next Year | $43.70 | $819.08 |
| P/E Ratio | $15.50 | ★ N/A |
| Revenue Growth | ★ 244.60 | N/A |
| 52 Week Low | $6.19 | $4.32 |
| 52 Week High | $13.16 | $17.66 |
Technical Indicators
Market Signals| Indicator | ZVRA | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 37.12 | 44.79 |
| Support Level | $8.12 | $9.69 |
| Resistance Level | $9.03 | $10.50 |
| Average True Range (ATR) | 0.36 | 0.56 |
| MACD | 0.01 | -0.08 |
| Stochastic Oscillator | 7.69 | 16.76 |
Price Performance
Historical ComparisonAbout ZVRA Zevra Therapeutics Inc.
Zevra Therapeutics Inc is a rare disease company combining science, data, and patient needs to create transformational therapies for diseases with limited or no treatment options. The company's mission is to bring life-changing therapeutics to people living with rare diseases. With data-driven development and commercialization strategies, it is overcoming complex drug development challenges to make new therapies available to the rare disease community.
About PRTA Prothena Corporation plc
Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.